Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease

References

• Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36:105–11
   PubMed Web of Science ®Google Scholar
• Hamilton-Fairley D, Kiddy D, Anyaoku V, et al. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol 1993;39: 363–7
   Google Scholar
• Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982;38:406–9
   PubMed Web of Science ®Google Scholar
• Harlass FE, Plymate SR, Fariss BL, etal. Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984;42:649–52
   PubMed Web of Science ®Google Scholar
• Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxypro-gesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997;82:556–60
   PubMed Web of Science ®Google Scholar
• Biitzow T, Lehtovirta M, Siegberg R, et al. The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women.J Clin Endocrinol Metab 2000;85:3271–5
   PubMed Web of Science ®Google Scholar
• Porte D Jr, Seeley RJ, Woods SC, et al. Obesity, diabetes and the central nervous system. Diabetologia 1998;41:863–81
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661–71
   PubMed Web of Science ®Google Scholar
• Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375–9
   PubMed Web of Science ®Google Scholar
• The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002;25 (Suppl 1):S5–20
   Google Scholar
• Dunaif A, Segal KR., Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–73
   PubMed Web of Science ®Google Scholar
• Luscombe GP, Hoperoft RH, Thomas PC, et al. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adreno-ceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989;28:129–34
   PubMed Web of Science ®Google Scholar
• Heal DJ, Cheetham SC, Prow MR., et al. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. BrJ Pharmacol 1998;125: 301–8
   Google Scholar
• Jackson H C, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613–18
   PubMed Web of Science ®Google Scholar
• Jackson HC, Needham AIVI, Hutchins LJ, et al. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997;121:1758–62
   PubMed Web of Science ®Google Scholar
• Stock MJ. Sibutramine: a review of the pharmacol-ogy of a novel anti obesity agent. Int J Obes 1997;21 (Suppl 1):525–9
   Google Scholar
• Heal DJ, Aspley S, Prow MR, et al. Sibutramine: a novel anti-obesity drug. A review of the pharma- cological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22 (Suppl 1):518–28
   Google Scholar
• Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsycho-pharmacol Biol Psychiatry 1988;12: 575–84
   Google Scholar
• Martin KF, Phillips I, Hearson M, et al. Character-ization of 8-0H-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol 1992;107:15–21
   PubMed Web of Science ®Google Scholar
• Hansen DL, Toubro S, Stock MJ, et al. Thermo-genic effects of sibutramine in humans. Am J Gun Nutr 1998;68:1180–6
   PubMed Web of Science ®Google Scholar
• Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restric-tion. Int J Obes 1999;23:1016–24
   PubMed Web of Science ®Google Scholar
• Stricker-Kongrad A, Souquet AIVI, Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced obesity: role of dietary constituents. Int J Obes 1995;19 (Suppl 2):145
   Google Scholar
• Rolls BJ, Shide DJ, Thorwart ML, et al. Sibu-tramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6:1–11
   PubMedGoogle Scholar
• Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126:1487–95
   PubMed Web of Science ®Google Scholar
• Liu YL, Heal DJ, Stock MJ. Mechanism of the thermogenic effect of metabolite 2 (BTS 54505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. IntJ Obes Relat Metab Disord 2002;26: 1245–53
   Google Scholar
• Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6:115–21
   Google Scholar